JonesTrading analyst Soumit Roy has maintained their bullish stance on NUVB stock, giving a Buy rating on June 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Soumit Roy has given his Buy rating due to a combination of factors influencing Nuvation Bio’s potential. The recent update by the National Comprehensive Cancer Network (NCCN) to include Nuvation Bio’s Ibtrozi as a preferred treatment option for ROS1+ Non-Small Cell Lung Cancer significantly enhances the company’s market position. This endorsement is pivotal as it applies to both initial and subsequent lines of therapy, indicating a broad application and acceptance of the drug.
Furthermore, Nuvation Bio’s robust financial standing, with approximately $461.7 million in cash and marketable securities, provides a solid foundation for continued research and development. The anticipation of Phase 2 data for safusidenib in IDH mutant glioma in the second half of 2025 is another key catalyst that could drive future growth. These elements collectively underpin the positive outlook and justify the Buy rating.
In another report released on June 17, RBC Capital also maintained a Buy rating on the stock with a $6.00 price target.
NUVB’s price has also changed moderately for the past six months – from $2.670 to $2.030, which is a -23.97% drop .